NSG 533 Exam 1 | Advanced Pharmacology | Wilkes University 2026/2027 Complete Guide with Questions and Verified Answers
NSG 533 / NSG 533 Exam 1 (Latest )
Advanced Pharmacology | Complete Guide with Questions and Verified Answers | 100%
Correct
Wilkes University - Nesbitt School of Pharmacy
Advanced Practice Pharmacology Education
100 Questions | 9 Sections | Comprehensive Rationales
Total Questions 100 (Multiple Choice, A-D)
9 Sections (PK/PD, Pharmacogenomics, Drug Interactions, Cardiovascular,
Sections
Antidiabetics, Psychotropics, Anti-infectives, Anticoagulants/Lipids, Clinical Scenarios)
Cognitive Levels 25% Recall | 55% Application | 20% Analysis
Format 75% Scenario-based | 20% Direct Recall | 5% Clinical Judgment
Section 1: Pharmacokinetics and Pharmacodynamics
Q1: A 45-year-old patient is prescribed a drug with high first-pass metabolism. The prescriber increases the
oral dose to achieve the desired therapeutic effect. Which of the following best explains why a higher oral dose
is needed compared to an intravenous dose of the same drug?
A. Oral bioavailability is 100% for this drug
B. Hepatic metabolism significantly reduces the fraction of drug reaching systemic circulation after oral
administration [CORRECT]
C. The drug has a very large volume of distribution when given orally
D. Protein binding is higher for oral formulations than intravenous formulations
Correct Answer: B
Rationale: First-pass metabolism occurs when a drug is absorbed from the GI tract and passes through the liver before reaching
systemic circulation. Drugs with high first-pass extraction (e.g., propranolol, morphine, lidocaine) have significantly reduced oral
bioavailability, requiring higher oral doses. This concept is foundational in the Wilkes NSG 533 pharmacokinetics module and directly
affects dose selection.
Q2: A patient with liver cirrhosis is started on a highly protein-bound drug (98% bound). The patient has
hypoalbuminemia with a serum albumin of 2.0 g/dL. What is the most likely clinical consequence of
administering this drug to this patient?
A. Decreased volume of distribution due to less free drug
B. Increased pharmacologic effect and higher risk of toxicity due to increased free drug fraction [CORRECT]
C. Enhanced renal clearance of the protein-bound fraction
D. No change in drug effect because protein binding is clinically insignificant
Correct Answer: B
Page 1
,NSG 533 Exam 1 | Advanced Pharmacology | Wilkes University 2026/2027 Complete Guide with Questions and Verified Answers
Rationale: Hypoalbuminemia reduces the number of available binding sites, increasing the free (unbound) fraction of highly
protein-bound drugs. Only free drug is pharmacologically active and available for metabolism and excretion, so the patient experiences
a greater drug effect at the same dose. The Wilkes NSG 533 curriculum emphasizes this as a critical consideration in hepatic and renal
disease.
Q3: A drug has a volume of distribution (Vd) of 400 L in a 70-kg patient. Which of the following best
characterizes this drug's tissue distribution?
A. The drug is primarily confined to the vascular compartment
B. The drug distributes mainly within extracellular fluid
C. The drug extensively distributes into tissues and possibly binds to tissue components [CORRECT]
D. The drug is sequestered in the intracellular space of the liver only
Correct Answer: C
Rationale: A Vd of 400 L in a 70-kg patient (total body water approximately 42 L) indicates the drug distributes well beyond plasma
and extracellular fluid into tissues. Drugs with high Vd values (e.g., digoxin, amiodarone) often exhibit extensive tissue binding or high
lipid solubility. The Wilkes NSG 533 pharmacokinetics section uses Vd calculations to predict loading doses and drug behavior.
Q4: A 60-year-old patient with a CNS infection is being treated with an antibiotic. Despite adequate serum
drug levels, the cerebrospinal fluid (CSF) drug concentration remains subtherapeutic. Which property of the
drug is most likely responsible for poor CNS penetration?
A. High lipid solubility and low molecular weight
B. Low lipid solubility and high degree of ionization at physiologic pH [CORRECT]
C. Active transport into the CNS via carrier-mediated uptake
D. Low protein binding in the plasma
Correct Answer: B
Rationale: The blood-brain barrier (BBB) restricts passage of hydrophilic and highly ionized molecules. Drugs that are lipophilic,
uncharged, and have low molecular weight cross the BBB more readily. The Wilkes NSG 533 curriculum highlights that P-glycoprotein
efflux transporters at the BBB further limit CNS penetration of many drugs, complicating treatment of CNS infections.
Q5: A patient taking warfarin (a CYP2C9 substrate) is started on fluconazole, a strong CYP2C9 inhibitor.
What is the most appropriate clinical management strategy?
A. Increase the warfarin dose to compensate for the interaction
B. Monitor INR closely and anticipate a need to decrease the warfarin dose [CORRECT]
C. Discontinue warfarin and switch to heparin permanently
D. No action is needed because fluconazole does not affect CYP2C9
Correct Answer: B
Rationale: Fluconazole inhibits CYP2C9, the primary enzyme responsible for S-warfarin metabolism, leading to increased warfarin
exposure and elevated INR. The Wilkes NSG 533 pharmacogenomics module emphasizes proactive INR monitoring and potential dose
reduction when CYP2C9 inhibitors are coadministered with warfarin to prevent serious bleeding.
Q6: A drug undergoes Phase II metabolism via glucuronidation. Compared to Phase I reactions, which of the
following is true regarding this metabolic pathway?
A. Phase II reactions typically produce pharmacologically active metabolites
B. Phase II reactions involve oxidation, reduction, or hydrolysis of the parent drug
C. Phase II reactions conjugate the drug or its Phase I metabolite to increase water solubility for renal
excretion [CORRECT]
D. Phase II reactions are primarily catalyzed by CYP450 enzymes
Correct Answer: C
Rationale: Phase II reactions (conjugation reactions) attach polar groups such as glucuronic acid, sulfate, or glutathione to the drug or
its Phase I metabolite, significantly increasing water solubility and promoting renal or biliary elimination. The Wilkes NSG 533
Page 2
, NSG 533 Exam 1 | Advanced Pharmacology | Wilkes University 2026/2027 Complete Guide with Questions and Verified Answers
curriculum contrasts Phase I (functionalization by CYP450) with Phase II (synthetic conjugation by transferases) metabolism.
Q7: A 70-year-old patient with a GFR of 30 mL/min is prescribed a renally cleared drug with a narrow
therapeutic index. The drug's normal half-life is 4 hours. Approximately what would be the expected half-life
in this patient?
A. 2 hours
B. 4 hours
C. 8 hours [CORRECT]
D. 16 hours
Correct Answer: C
Rationale: Half-life is inversely proportional to clearance. If GFR decreases by 50% (from 60 to 30 mL/min, assuming the drug is
primarily renally cleared), the half-life approximately doubles from 4 to 8 hours. The Wilkes NSG 533 pharmacokinetics curriculum
stresses the importance of adjusting dosing intervals for renally cleared drugs in patients with decreased GFR.
Q8: A patient taking oral contraceptives begins taking rifampin for tuberculosis treatment. Two months later,
she reports breakthrough bleeding and an unplanned pregnancy. Which pharmacokinetic mechanism best
explains this interaction?
A. Rifampin inhibits CYP3A4, increasing estrogen levels
B. Rifampin induces CYP3A4 and increases hepatic metabolism of contraceptive steroids, reducing their
bioavailability [CORRECT]
C. Rifampin decreases renal clearance of contraceptive hormones
D. Rifampin competitively blocks estrogen receptors in the endometrium
Correct Answer: B
Rationale: Rifampin is a potent CYP3A4 inducer that increases the hepatic metabolism of estrogen and progestin components of oral
contraceptives, significantly reducing their bioavailability and contraceptive efficacy. The Wilkes NSG 533 curriculum identifies
rifampin as a classic example of enzyme induction causing therapeutic failure.
Q9: Enterohepatic recirculation of a drug results in which of the following pharmacokinetic effects?
A. Shortened drug half-life and rapid elimination
B. Prolonged drug half-life and a secondary peak in the plasma concentration-time curve [CORRECT]
C. Decreased bioavailability due to destruction in the intestinal lumen
D. Increased first-pass metabolism on subsequent passes through the liver
Correct Answer: B
Rationale: Enterohepatic recirculation occurs when a drug is conjugated in the liver, excreted in bile, deconjugated by intestinal bacteria,
and then reabsorbed. This process prolongs the drug's half-life and can produce a secondary plasma concentration peak. The Wilkes
NSG 533 pharmacokinetics module notes that drugs like doxycycline and oral contraceptives undergo this process.
Q10: A drug acts by binding to a G-protein-coupled receptor (GPCR) on vascular smooth muscle cells,
activating Gs proteins and increasing intracellular cAMP. Which of the following describes the receptor type
and a likely drug with this mechanism?
A. Ligand-gated ion channel; benzodiazepine
B. Enzyme-linked receptor; insulin
C. G-protein-coupled receptor; albuterol (beta-2 agonist) [CORRECT]
D. Intracellular receptor; prednisone
Correct Answer: C
Rationale: Beta-2 adrenergic receptors are GPCRs coupled to Gs proteins that stimulate adenylate cyclase, increasing cAMP and
causing smooth muscle relaxation. The Wilkes NSG 533 pharmacodynamics curriculum maps each receptor class (ligand-gated ion
channels, GPCRs, enzyme-linked receptors, intracellular receptors) to their signal transduction pathways and clinical drug examples.
Page 3
NSG 533 / NSG 533 Exam 1 (Latest )
Advanced Pharmacology | Complete Guide with Questions and Verified Answers | 100%
Correct
Wilkes University - Nesbitt School of Pharmacy
Advanced Practice Pharmacology Education
100 Questions | 9 Sections | Comprehensive Rationales
Total Questions 100 (Multiple Choice, A-D)
9 Sections (PK/PD, Pharmacogenomics, Drug Interactions, Cardiovascular,
Sections
Antidiabetics, Psychotropics, Anti-infectives, Anticoagulants/Lipids, Clinical Scenarios)
Cognitive Levels 25% Recall | 55% Application | 20% Analysis
Format 75% Scenario-based | 20% Direct Recall | 5% Clinical Judgment
Section 1: Pharmacokinetics and Pharmacodynamics
Q1: A 45-year-old patient is prescribed a drug with high first-pass metabolism. The prescriber increases the
oral dose to achieve the desired therapeutic effect. Which of the following best explains why a higher oral dose
is needed compared to an intravenous dose of the same drug?
A. Oral bioavailability is 100% for this drug
B. Hepatic metabolism significantly reduces the fraction of drug reaching systemic circulation after oral
administration [CORRECT]
C. The drug has a very large volume of distribution when given orally
D. Protein binding is higher for oral formulations than intravenous formulations
Correct Answer: B
Rationale: First-pass metabolism occurs when a drug is absorbed from the GI tract and passes through the liver before reaching
systemic circulation. Drugs with high first-pass extraction (e.g., propranolol, morphine, lidocaine) have significantly reduced oral
bioavailability, requiring higher oral doses. This concept is foundational in the Wilkes NSG 533 pharmacokinetics module and directly
affects dose selection.
Q2: A patient with liver cirrhosis is started on a highly protein-bound drug (98% bound). The patient has
hypoalbuminemia with a serum albumin of 2.0 g/dL. What is the most likely clinical consequence of
administering this drug to this patient?
A. Decreased volume of distribution due to less free drug
B. Increased pharmacologic effect and higher risk of toxicity due to increased free drug fraction [CORRECT]
C. Enhanced renal clearance of the protein-bound fraction
D. No change in drug effect because protein binding is clinically insignificant
Correct Answer: B
Page 1
,NSG 533 Exam 1 | Advanced Pharmacology | Wilkes University 2026/2027 Complete Guide with Questions and Verified Answers
Rationale: Hypoalbuminemia reduces the number of available binding sites, increasing the free (unbound) fraction of highly
protein-bound drugs. Only free drug is pharmacologically active and available for metabolism and excretion, so the patient experiences
a greater drug effect at the same dose. The Wilkes NSG 533 curriculum emphasizes this as a critical consideration in hepatic and renal
disease.
Q3: A drug has a volume of distribution (Vd) of 400 L in a 70-kg patient. Which of the following best
characterizes this drug's tissue distribution?
A. The drug is primarily confined to the vascular compartment
B. The drug distributes mainly within extracellular fluid
C. The drug extensively distributes into tissues and possibly binds to tissue components [CORRECT]
D. The drug is sequestered in the intracellular space of the liver only
Correct Answer: C
Rationale: A Vd of 400 L in a 70-kg patient (total body water approximately 42 L) indicates the drug distributes well beyond plasma
and extracellular fluid into tissues. Drugs with high Vd values (e.g., digoxin, amiodarone) often exhibit extensive tissue binding or high
lipid solubility. The Wilkes NSG 533 pharmacokinetics section uses Vd calculations to predict loading doses and drug behavior.
Q4: A 60-year-old patient with a CNS infection is being treated with an antibiotic. Despite adequate serum
drug levels, the cerebrospinal fluid (CSF) drug concentration remains subtherapeutic. Which property of the
drug is most likely responsible for poor CNS penetration?
A. High lipid solubility and low molecular weight
B. Low lipid solubility and high degree of ionization at physiologic pH [CORRECT]
C. Active transport into the CNS via carrier-mediated uptake
D. Low protein binding in the plasma
Correct Answer: B
Rationale: The blood-brain barrier (BBB) restricts passage of hydrophilic and highly ionized molecules. Drugs that are lipophilic,
uncharged, and have low molecular weight cross the BBB more readily. The Wilkes NSG 533 curriculum highlights that P-glycoprotein
efflux transporters at the BBB further limit CNS penetration of many drugs, complicating treatment of CNS infections.
Q5: A patient taking warfarin (a CYP2C9 substrate) is started on fluconazole, a strong CYP2C9 inhibitor.
What is the most appropriate clinical management strategy?
A. Increase the warfarin dose to compensate for the interaction
B. Monitor INR closely and anticipate a need to decrease the warfarin dose [CORRECT]
C. Discontinue warfarin and switch to heparin permanently
D. No action is needed because fluconazole does not affect CYP2C9
Correct Answer: B
Rationale: Fluconazole inhibits CYP2C9, the primary enzyme responsible for S-warfarin metabolism, leading to increased warfarin
exposure and elevated INR. The Wilkes NSG 533 pharmacogenomics module emphasizes proactive INR monitoring and potential dose
reduction when CYP2C9 inhibitors are coadministered with warfarin to prevent serious bleeding.
Q6: A drug undergoes Phase II metabolism via glucuronidation. Compared to Phase I reactions, which of the
following is true regarding this metabolic pathway?
A. Phase II reactions typically produce pharmacologically active metabolites
B. Phase II reactions involve oxidation, reduction, or hydrolysis of the parent drug
C. Phase II reactions conjugate the drug or its Phase I metabolite to increase water solubility for renal
excretion [CORRECT]
D. Phase II reactions are primarily catalyzed by CYP450 enzymes
Correct Answer: C
Rationale: Phase II reactions (conjugation reactions) attach polar groups such as glucuronic acid, sulfate, or glutathione to the drug or
its Phase I metabolite, significantly increasing water solubility and promoting renal or biliary elimination. The Wilkes NSG 533
Page 2
, NSG 533 Exam 1 | Advanced Pharmacology | Wilkes University 2026/2027 Complete Guide with Questions and Verified Answers
curriculum contrasts Phase I (functionalization by CYP450) with Phase II (synthetic conjugation by transferases) metabolism.
Q7: A 70-year-old patient with a GFR of 30 mL/min is prescribed a renally cleared drug with a narrow
therapeutic index. The drug's normal half-life is 4 hours. Approximately what would be the expected half-life
in this patient?
A. 2 hours
B. 4 hours
C. 8 hours [CORRECT]
D. 16 hours
Correct Answer: C
Rationale: Half-life is inversely proportional to clearance. If GFR decreases by 50% (from 60 to 30 mL/min, assuming the drug is
primarily renally cleared), the half-life approximately doubles from 4 to 8 hours. The Wilkes NSG 533 pharmacokinetics curriculum
stresses the importance of adjusting dosing intervals for renally cleared drugs in patients with decreased GFR.
Q8: A patient taking oral contraceptives begins taking rifampin for tuberculosis treatment. Two months later,
she reports breakthrough bleeding and an unplanned pregnancy. Which pharmacokinetic mechanism best
explains this interaction?
A. Rifampin inhibits CYP3A4, increasing estrogen levels
B. Rifampin induces CYP3A4 and increases hepatic metabolism of contraceptive steroids, reducing their
bioavailability [CORRECT]
C. Rifampin decreases renal clearance of contraceptive hormones
D. Rifampin competitively blocks estrogen receptors in the endometrium
Correct Answer: B
Rationale: Rifampin is a potent CYP3A4 inducer that increases the hepatic metabolism of estrogen and progestin components of oral
contraceptives, significantly reducing their bioavailability and contraceptive efficacy. The Wilkes NSG 533 curriculum identifies
rifampin as a classic example of enzyme induction causing therapeutic failure.
Q9: Enterohepatic recirculation of a drug results in which of the following pharmacokinetic effects?
A. Shortened drug half-life and rapid elimination
B. Prolonged drug half-life and a secondary peak in the plasma concentration-time curve [CORRECT]
C. Decreased bioavailability due to destruction in the intestinal lumen
D. Increased first-pass metabolism on subsequent passes through the liver
Correct Answer: B
Rationale: Enterohepatic recirculation occurs when a drug is conjugated in the liver, excreted in bile, deconjugated by intestinal bacteria,
and then reabsorbed. This process prolongs the drug's half-life and can produce a secondary plasma concentration peak. The Wilkes
NSG 533 pharmacokinetics module notes that drugs like doxycycline and oral contraceptives undergo this process.
Q10: A drug acts by binding to a G-protein-coupled receptor (GPCR) on vascular smooth muscle cells,
activating Gs proteins and increasing intracellular cAMP. Which of the following describes the receptor type
and a likely drug with this mechanism?
A. Ligand-gated ion channel; benzodiazepine
B. Enzyme-linked receptor; insulin
C. G-protein-coupled receptor; albuterol (beta-2 agonist) [CORRECT]
D. Intracellular receptor; prednisone
Correct Answer: C
Rationale: Beta-2 adrenergic receptors are GPCRs coupled to Gs proteins that stimulate adenylate cyclase, increasing cAMP and
causing smooth muscle relaxation. The Wilkes NSG 533 pharmacodynamics curriculum maps each receptor class (ligand-gated ion
channels, GPCRs, enzyme-linked receptors, intracellular receptors) to their signal transduction pathways and clinical drug examples.
Page 3
